Open mobile menu
Blue Background
Insights

News

Stay up to date with news about Secerna and intellectual property topics.

The Edge Of Exclusivity From Revenue Cliff To Biosimilar Slope

The Edge of Exclusivity: From Revenue Cliff to Biosimilar Slope

News 05/05/2026

As we move through 2026 towards 2030, the pharmaceutical industry is no longer approaching the ‘super cliff’ but has already stepped off the edge and is part way down it. 

Read more
18 19 20 21 22 23 24 25 26 27 28